25,729 articles
Epley maneuver
The Epley maneuver, also called the canalith repositioning procedure, is a sequence of timed head and body positions used to treat benign paroxysmal positional vertigo.
Eplivanserin
Eplivanserin (SR-46349, Sliwens) is a selective 5-HT2A receptor antagonist Sanofi developed for sleep-maintenance insomnia; its EU marketing application was withdrawn in December 2009 after CHMP concerns over small effect and diverticulitis risk.
Eplontersen
Eplontersen (Wainua, Wainzua) is a GalNAc-conjugated antisense oligonucleotide silencing liver TTR mRNA, FDA-approved December 2023 at 45 mg monthly subcutaneously for hereditary transthyretin amyloidosis polyneuropathy; its ATTR-CM trial failed.
EPOCH chemotherapy regimen
EPOCH is a combination chemotherapy regimen of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, with the natural-product drugs given by continuous infusion; it is used mainly for aggressive B-cell non-Hodgkin lymphoma, and adding rituximab gives R-EPOCH.
Epoetin beta
Epoetin beta (Recormon, NeoRecormon) is a recombinant human erythropoietin made in CHO cells, approved in Europe in 1990 by Boehringer Mannheim and reformulated by Roche in 1997, used for renal and cancer anemia; not US-approved.
Epoetin delta
Epoetin delta (Dynepo) was the only epoetin made in a human cell line (HT-1080), EU-approved 18 March 2002 for anemia of chronic renal failure in adults and withdrawn 17 March 2009 for commercial reasons.
Epoetin theta
Epoetin theta (Eporatio, Biopoin) is a CHO-cell recombinant human erythropoietin approved by EMA in 2009 for symptomatic anemia in adults with chronic renal failure or non-myeloid cancer on chemotherapy, dosed 20,000 IU weekly.
Epoetin zeta
Epoetin zeta (Retacrit, Silapo; US name epoetin alfa-epbx) is a biosimilar recombinant human erythropoietin made in CHO cells, EU-authorized 18 December 2007 against epoetin alfa (Eprex/Erypo) and FDA-approved 2018, used for renal, chemotherapy-related, and surgical anemia.
EPOOzo-2 study
EPOOzo-2 (NCT07325851) is a prospective observational study of 120 patients receiving palliative ozone therapy at Dr. Negrín University Hospital's Chronic Pain Unit, Gran Canaria, Spain, 2026-2029, measuring quality of life.
Epratuzumab
Epratuzumab (AMG 412, hLL2, LymphoCide) is a humanized anti-CD22 IgG1 monoclonal antibody with partial B-cell depletion, tested in SLE through phase III EMBODY trials, which failed, leaving it unapproved.
Eprenetapopt
Eprenetapopt (APR-246, PRIMA-1MET) is an investigational small-molecule p53 reactivator prodrug converted to methylene quinuclidinone; developed by Aprea Therapeutics for TP53-mutant MDS/AML, its phase 3 trial missed its primary endpoint and it is not FDA approved.
Epristeride
Epristeride (爱普列特) is a noncompetitive 5α-reductase inhibitor for benign prostatic hyperplasia, developed in China, approved as a class-1 new drug in 1999, and marketed by Lianhuan Pharmaceutical.
Eprodisate
Eprodisate (Kiacta, Fibrillex, NC-503; 1,3-propanedisulfonic acid disodium salt) is an investigational sulfonated inhibitor of amyloid fibril polymerization for AA amyloidosis kidney disease; its first phase 3 trial was positive but a confirmatory trial failed and it was never approved.
Eprosartan
Eprosartan (Teveten) is a non-biphenyl, non-tetrazole angiotensin II receptor blocker for hypertension, dosed 600-800 mg daily, selective for the AT1 receptor and not metabolized by cytochrome P450.
Eprotirome
Eprotirome (KB2115), a liver-selective thyroid hormone receptor beta agonist from Karo Bio, lowered LDL cholesterol, triglycerides, and Lp(a) in trials but was abandoned after canine cartilage damage and liver injury ended its phase 3 AKKA trial.
Epstein-Barr virus-associated gastric carcinoma
Epstein-Barr virus-associated gastric carcinoma (EBVaGC), EBV-positive gastric cancer, is a molecular subtype of gastric carcinoma defined by latent EBV in tumor cells, about 8-10% of cases, male-predominant, proximal, with favorable prognosis and PD-L1 expression.
Epstein-Barr virus-positive diffuse large B-cell lymphoma
EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL, NOS), formerly EBV+ DLBCL of the elderly, is an aggressive EBV-carrying B-cell lymphoma of patients over 50 without immunodeficiency, diagnosed by EBER, treated with R-CHOP, with worse prognosis than EBV-negative DLBCL.
Eptacog alfa (activated)
Eptacog alfa (activated), brand NovoSeven/NovoSeven RT (Novo Nordisk), is recombinant activated factor VIIa, a bypassing agent for bleeding in hemophilia with inhibitors, factor VII deficiency, and Glanzmann's thrombasthenia; EU/US approvals 1996/1999, EU shortages through 2025.
Eptifibatide
Eptifibatide (brand name Integrilin) is a synthetic cyclic heptapeptide drug that inhibits platelet aggregation by blocking the glycoprotein IIb/IIIa receptor, approved in 1998 for acute coronary syndrome and coronary intervention.
Eptinezumab
Eptinezumab (Vyepti, ALD403, eptinezumab-jjmr) is a humanized anti-CGRP monoclonal antibody given as a 100 or 300 mg intravenous infusion every 12 weeks to prevent migraine in adults; FDA approved February 2020, developed by Alder and acquired by Lundbeck.
EpVAr2019 study
EpVAr2019 (NCT04107467), a prospective multicenter observational study of mechanical ventilation epidemiology in Argentine ICUs, Sept-Dec 2019; 950 patients, 142 units; ICU mortality 44.6%, hospital 47.9%.
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a self-administered questionnaire rating dozing likelihood in eight everyday situations, scored 0-24, introduced by Murray Johns in 1991 and widely used in sleep medicine.
EQ-5D
The EQ-5D is a standardized, self-administered questionnaire measuring health-related quality of life across five dimensions, developed by the EuroQol Group and widely used for computing QALYs in health technology assessment.
Equecabtagene autoleucel
Equecabtagene autoleucel (伊基奥仑赛, Fucaso) is a fully human BCMA-directed autologous CAR-T therapy by IASO Bio, conditionally approved by China's NMPA on June 30, 2023 for relapsed/refractory multiple myeloma after at least three prior lines.
Equianalgesic
Equianalgesic dose: an opioid dose giving pain relief equivalent to a reference dose, usually oral or parenteral morphine. Tables guide opioid rotation but ratios vary, are unidirectional, and require 25–50% dose reduction for incomplete cross-tolerance.
Equine lymphangitis
Equine lymphangitis, also called big leg, is inflammation of a horse's limb lymphatic vessels, usually bacterial (Corynebacterium pseudotuberculosis ulcerative lymphangitis) or sporadic from immobility; treated with longterm antimicrobials and drainage.
Equine-assisted therapy
Equine-assisted therapy, also called hippotherapy or equine-assisted psychotherapy, is treatment using horses by licensed therapists; the field's umbrella term is equine-assisted services (EAS), covering therapy, learning, and horsemanship.
Equivalence trial
An equivalence trial is a clinical trial designed to show a new treatment works about as well as an existing one within a predefined acceptable margin.
Eradication of dracunculiasis
The eradication of dracunculiasis (guinea-worm disease) is a global health campaign led by The Carter Center, which cut cases from 3.5 million in 1986 to 10 in 2025.
Eradication of infectious diseases
Eradication of infectious diseases: permanent worldwide zero of a pathogen by deliberate effort. Smallpox only human success (1980); Guinea worm and polio campaigns ongoing; malaria, measles assessed.